Business
Schrödinger to Present New Preclinical Data From Its MALT1 Inhibitor Program at ASH 2021 Annual Meeting
NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are
About this update from Schrodinger, Inc.
[{"type":"text","content":" NEW YORK--(BUSINESS WIRE)--\nSchrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that new preclinical data on its small-molecule MALT1 inhibitors will be presented during a poster session at the American Society of Hematology (ASH) 63rd Annual Meeting taking place virtually and in Atlanta, Georgia, December 11-14, 2021.\n\nInhibiting MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) is considered a potentially promising therapeutic approach for the treatment of certain subtypes of non-Hodgkin B-cell lymphomas and for chronic lymphocytic leukemia (CLL). Schrödinger has identified a number of small-molecule MALT1 inhibitors, the most advanced of which is expected to enter the clinic next year.\n\nDetails of the poster presentation are as follows:\n\nTitle: Characterization of Potent Paracaspase MALT1 Inhibitors for Hematological Malignancies\nAbstract number: 1187\nDate & time: Saturday, December 11, 5:30 p.m. - 7:30 p.m. EST\nLocation: Georgia World Congress Center, Hall B5\n\nAbout Schrödinger\n\nSchrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.\n\nFounded in 1990, Schrödinger has over 500 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com and follow us on LinkedIn and Twitter.\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to those regarding the expected timing of clinical trials for Schrödinger’s MALT1 inhibitor program, and the potential of MALT1 inhibitors to be used fo...